Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It localizes in viable myocardial cells in proportion to regional blood flow, allowing clinicians to assess coronary artery disease, myocardial viability, and ischemia in adult patients undergoing cardiac imaging.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides reliable sourcing, regulatory support, and logistics for clinical and research facilities across multiple regions, ensuring timely delivery and compliance with local import requirements.

Tetrofosmin is used in cardiac imaging to evaluate myocardial perfusion and viability.

Coronary artery disease detection: Enables SPECT myocardial perfusion imaging to identify perfusion defects and assess the extent of coronary artery disease. Myocardial viability assessment: Highlights viable myocardial tissue after ischemic injury, supporting decisions regarding revascularization. Ischemia evaluation: Detects regional perfusion abnormalities during stress testing to differentiate reversible ischemia from scar tissue.

Adverse reactions to Myoview are generally infrequent but may occur following administration of the radiopharmaceutical.

Common Side Effects: - Mild nausea: transient feeling of queasiness after injection. - Headache: brief, mild headache reported in some patients. - Flushing: temporary warmth or redness at the injection site.

Serious or Rare Side Effects: - Allergic reaction: urticaria, bronchospasm, or anaphylaxis requiring immediate medical attention. - Radiation‑induced skin erythema: localized reddening at the injection site persisting for days. - Cardiac arrhythmia: rare occurrence of new or worsening rhythm disturbances during imaging.

When using Myoview, several precautions should be observed to ensure patient safety and optimal image quality.

Pregnancy: avoid use unless clearly needed, as fetal radiation exposure cannot be excluded. Breastfeeding: discontinue nursing for an appropriate period after administration, based on local guidelines. Renal impairment: consider reduced clearance; adjust imaging timing if necessary. Concurrent cardiac stress agents: verify compatibility with pharmacologic stress protocols. Allergy history: screen for prior reactions to radiopharmaceuticals or iodine‑containing compounds. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with other agents that affect cardiac imaging or radiation exposure.

Major Interactions (Avoid): - Thyroid hormone therapy: can alter iodine metabolism, potentially affecting radiotracer distribution. - High‑dose iodinated contrast: may compete for uptake pathways and reduce image quality.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt heart rate response during pharmacologic stress, influencing perfusion results. - Calcium channel blockers: can modify coronary vasodilation, requiring protocol adjustments. - Other radiopharmaceuticals: schedule sufficient interval to prevent cumulative radiation dose.